Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$161.72
-0.6%
$174.01
$130.96
$182.89
$286.35B0.585.66 million shs5.17 million shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$44.21
+0.6%
$50.81
$43.73
$69.10
$89.62B0.3915.96 million shs13.24 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$776.75
-0.6%
$761.41
$399.26
$800.78
$738.04B0.343.07 million shs2.76 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$129.21
+0.7%
$127.05
$75.56
$138.28
$579.83B0.414.80 million shs4.88 million shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.72%-4.04%-10.66%-1.02%+5.84%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-1.55%-10.29%-18.94%-10.05%-35.73%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+6.00%+4.82%+0.46%+21.15%+92.59%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.07%-0.26%-0.09%+11.85%+206.49%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.8183 of 5 stars
2.43.04.23.93.12.52.5
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.9397 of 5 stars
4.14.02.54.02.81.71.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.688 of 5 stars
2.43.02.54.02.61.73.1
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.257 of 5 stars
1.43.02.50.02.50.03.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$174.317.78% Upside
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.11
Hold$60.0035.72% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$757.95-2.42% Downside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.75
Moderate Buy$133.603.40% Upside

Current Analyst Ratings

Latest ABBV, NVO, LLY, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$900.00 ➝ $1,001.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$850.00 ➝ $900.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$850.00 ➝ $892.00
4/30/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00 ➝ $885.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$195.00 ➝ $187.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$195.00 ➝ $180.00
4/26/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$55.00 ➝ $48.00
4/26/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $43.00
4/18/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $52.00
4/18/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
(Data available from 5/1/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.27$15.84 per share10.21$5.78 per share27.98
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$45.01B1.99$12.35 per share3.58$8.16 per share5.42
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B21.63$8.04 per share96.66$11.44 per share67.90
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$33.71B17.20$3.07 per share42.14$3.45 per share37.45

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$3.3747.9913.382.0411.02%165.18%14.40%7/25/2024 (Estimated)
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$8.03B-$3.10N/A6.3215.39-13.50%8.83%2.50%7/25/2024 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80133.9241.991.6115.36%51.22%9.94%8/13/2024 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$12.15B$2.7147.7731.592.1236.03%90.36%29.18%5/2/2024 (Confirmed)

Latest ABBV, NVO, LLY, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77N/A-$0.77N/AN/AN/A  
4/30/2024Q1 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.53$2.58+$0.05$2.68$8.94 billion$8.77 billion      
4/26/2024Q1 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.26$2.31+$0.05$3.85$11.93 billion$12.31 billion    
4/25/2024Q1 24
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$4.53-$4.40+$0.13$9.69$11.45 billion$11.87 billion      
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
2/2/202412/31/2023
AbbVie Inc. stock logo
ABBV
AbbVie
$2.76$2.79+$0.03$5.12$14.02 billion$14.30 billion    
2/2/202412/31/2023
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.55$1.70+$0.15$2.53$11.19 billion$11.48 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.83%+7.84%183.98%52 Years
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.405.43%+8.20%N/A N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.67%+15.15%89.66%10 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.331.03%+16.52%49.17%1 Years

Latest ABBV, NVO, LLY, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
3/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.604.72%4/4/20244/5/20245/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.99
1.11
0.99
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.19
0.82
0.64

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,1002.03 billion2.03 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
63,3704.49 billion4.48 billionOptionable

ABBV, NVO, LLY, and BMY Headlines

SourceHeadline
RB Capital Management LLC Purchases New Shares in Novo Nordisk A/S (NYSE:NVO)RB Capital Management LLC Purchases New Shares in Novo Nordisk A/S (NYSE:NVO)
marketbeat.com - May 1 at 4:30 PM
Novo Nordisk A/S (NYSE:NVO) Trading Up 0.4%Novo Nordisk A/S (NYSE:NVO) Trading Up 0.4%
marketbeat.com - May 1 at 2:29 PM
Profit from the Panic: 3 Stocks to Pounce on When They Become StealsProfit from the Panic: 3 Stocks to Pounce on When They Become Steals
investorplace.com - May 1 at 1:41 PM
Heres what to expect from Novo Nordisk (spons ADRs)s earnings reportHere's what to expect from Novo Nordisk (spons ADRs)'s earnings report
markets.businessinsider.com - May 1 at 1:19 PM
Danish Medicines Agency Says Type 2 Diabetes Patients Should Start Treatment With Cheaper DrugsDanish Medicines Agency Says Type 2 Diabetes Patients Should Start Treatment With 'Cheaper' Drugs
finance.yahoo.com - May 1 at 1:19 PM
Novo Nordisk A/S - share repurchase programmeNovo Nordisk A/S - share repurchase programme
globenewswire.com - May 1 at 8:30 AM
Ozempic Subsidies Cut in Novo Nordisk’s Home Country of DenmarkOzempic Subsidies Cut in Novo Nordisk’s Home Country of Denmark
bloomberg.com - May 1 at 7:39 AM
Anticipating Novo Nordisk Earnings Amidst Surge in Weight Loss Drug Sales: 3 Key Factors to MonitorAnticipating Novo Nordisk Earnings Amidst Surge in Weight Loss Drug Sales: 3 Key Factors to Monitor
msn.com - May 1 at 7:39 AM
Three things to look out for when Novo Nordisk reports its first quarter earningsThree things to look out for when Novo Nordisk reports its first quarter earnings
msn.com - May 1 at 7:39 AM
Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetesDenmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes
finance.yahoo.com - May 1 at 7:39 AM
UPDATE 1-Novo Nordisk owner to invest $200 million in quantum computing startupsUPDATE 1-Novo Nordisk owner to invest $200 million in quantum computing startups
finance.yahoo.com - May 1 at 7:39 AM
The Ozempic Effect: How a Weight Loss Wonder Drug Gobbled Up an Entire EconomyThe Ozempic Effect: How a Weight Loss Wonder Drug Gobbled Up an Entire Economy
finance.yahoo.com - May 1 at 7:39 AM
Novo Nordisk owner to invest $200 million in quantum computing startupsNovo Nordisk owner to invest $200 million in quantum computing startups
reuters.com - May 1 at 3:02 AM
What Novo Nordisks Ozempic Success Means for DenmarkWhat Novo Nordisk's Ozempic Success Means for Denmark
bloomberg.com - May 1 at 2:38 AM
Novo Nordisk A/S (NYSE:NVO) Trading Up 1.8%Novo Nordisk A/S (NYSE:NVO) Trading Up 1.8%
marketbeat.com - April 30 at 4:31 PM
3 of Europes ‘Magnificent 18 Stocks That You Can Buy in the U.S.3 of Europe's ‘Magnificent 18' Stocks That You Can Buy in the U.S.
investorplace.com - April 30 at 4:30 PM
Eli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024Eli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024
finance.yahoo.com - April 30 at 2:13 PM
FTC challenges junk patents held by 10 drugmakers, including for Novo Nordisks OzempicFTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
cnbc.com - April 30 at 1:48 PM
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
zacks.com - April 30 at 12:21 PM
FDA calls for adcomm to discuss Novo Nordisks filing for weekly insulinFDA calls for adcomm to discuss Novo Nordisk's filing for weekly insulin
fiercepharma.com - April 29 at 6:08 PM
Decoding Novo Nordisks Options Activity: Whats the Big Picture?Decoding Novo Nordisk's Options Activity: What's the Big Picture?
benzinga.com - April 29 at 6:08 PM
Heres Why Novo Nordisk Stock Is a Buy Right NowHere's Why Novo Nordisk Stock Is a Buy Right Now
msn.com - April 29 at 6:08 PM
Novo Nordisk A/S (NYSE:NVO) Shares Up 0.2%Novo Nordisk A/S (NYSE:NVO) Shares Up 0.2%
marketbeat.com - April 29 at 3:51 PM
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
zacks.com - April 29 at 2:35 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Novo Nordisk A/S logo

Novo Nordisk A/S

NYSE:NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.